CorMedix to acquire substantially all assets of Heron Therapeutics
FROM THE WIRE · FINANCE.YAHOO.COM
Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralA deal relevant to both companies, paid in cash and CorMedix shares.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Upfront consideration includes $145 million in cash and 14,583,333 CorMedix common shares.
- 02Up to $55 million in earn-out payments are tied to 2028 ZYNRELEF net sales.
- 03The deal adds four commercial-stage products to CorMedix's portfolio.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
CorMedix Inc.5.32 USDMarket closedtoday +1.72%Neutral Heron Therapeutics, Inc.0.2930 USDMarket closedtoday +4.64%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets